Glaxosmithkline Pharmaceuticals Limited (GLAXO)
ISIN: - Industry: Drug Manufacturers—General Sector: Healthcare Website
1334.2
-4.85(-0.36%)

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Pricing Updates

TODAY'S HIGH

1341

TODAY'S LOW

1327.65

52 WEEK HIGH

1918.75

52 WEEK LOW

1295.95

Major Holders

% of Shares Held by
All Insider

75.57%

% of Shares Held by
Institutions

11.11%

% of Float Held by
Institutions

45.47%

Number of Institutions
Holding Shares

45

Company Overview

MARKET CAP

22602.94 Cr.

ETERPRISE VALUE

21397.43 Cr.

NO. OF SHARES

16.94 Cr.

BOOK VALUE

85.901

DIV. YIELD

60%

DEBT

23.24 Cr.

GROSS PROFIT

1899.81 Cr.

CASH

1305.23 Cr.

REVENUE

3287.51 Cr.

REVENUE/SHARE

194.087

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Investments-1812.38 Cr.225 Cr.92 Cr.20 Cr.
Change To Liabilities102.37 Cr.107.40 Cr.-48.22 Cr.-100.04 Cr.
Total cashflows from Investing Activities-405.50 Cr.418.59 Cr.-56.84 Cr.-153.45 Cr.
Net Borrowings-15.61 Cr.-14.98 Cr.-15.05 Cr.-40.60 Lakhs
Total Cash from Financing Activities-524.24 Cr.-696.13 Cr.-427.62 Cr.-358.35 Cr.
Other Liabilities-4.72 Cr.85.07 Cr.160.06 Cr.55.26 Cr.
Total Assets0000
Net Income1694.72 Cr.358.14 Cr.93.20 Cr.445.39 Cr.
Change in Cash-119 Cr.300.37 Cr.6.03 Cr.-102.32 Cr.
Effect of Exchange Rate0000
Total Cash from Operating Activities810.74 Cr.577.92 Cr.490.49 Cr.409.48 Cr.
Depreciation68.19 Cr.70.25 Cr.72.89 Cr.38.83 Cr.
Other Cashflows from Investing Activities1408 Cr.55.30 Cr.3.55 Cr.69.78 Cr.
Dividends Paid-506.64 Cr.-677.62 Cr.-338.81 Cr.-296.46 Cr.
Change to Inventory12 Cr.-46.79 Cr.-67.71 Cr.13.68 Cr.
Change to Account Receivables10.20 Cr.-99.93 Cr.-4.97 Lakhs26.89 Cr.
Other Cashflows from Financing Activities-1.99 Cr.-3.53 Cr.-73.75 Cr.-61.49 Cr.
Change to Net Income-1072.02 Cr.94.73 Cr.270.54 Cr.-80.30 Cr.
Capital Expenditures-34.64 Cr.-44.22 Cr.-155.89 Cr.-291.28 Cr.

Financials

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Research DevelopmentNoneNoneNoneNone
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax779.05 Cr.550.49 Cr.305.75 Cr.682.66 Cr.
Minority InterestNoneNoneNoneNone
Net Income693.69 Cr.616.10 Cr.586.93 Cr.557.06 Cr.
Selling General Administrative610.23 Cr.747.05 Cr.774.14 Cr.692.54 Cr.
Gross Profit1921.84 Cr.1864.66 Cr.1899.37 Cr.1749.27 Cr.
Ebit693.69 Cr.616.10 Cr.586.93 Cr.557.06 Cr.
Operating Income693.69 Cr.616.10 Cr.586.93 Cr.557.06 Cr.
Other Operating Expenses549.73 Cr.422.40 Cr.455.98 Cr.451.64 Cr.
Interest Expense-2 Cr.-3.53 Cr.-6.33 Cr.-55.43 Lakhs
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense398.28 Cr.192.35 Cr.212.54 Cr.237.27 Cr.
Total Revenue3278.03 Cr.3198.86 Cr.3224.38 Cr.3128.11 Cr.
Total Operating Expenses2584.34 Cr.2582.75 Cr.2637.44 Cr.2571.05 Cr.
Cost of Revenue1356.19 Cr.1334.19 Cr.1325 Cr.1378.84 Cr.
Total Other Income Expense Net85.36 Cr.-65.60 Cr.-281.18 Cr.125.60 Cr.
Discontinued Operations1313.95 Cr.1313.95 Cr.1313.95 Cr.1313.95 Cr.
Net Income from Continuous Ops.380.77 Cr.358.14 Cr.93.20 Cr.445.39 Cr.
Net Income Applicable to Common Shares1694.72 Cr.358.14 Cr.93.20 Cr.445.39 Cr.

Balance Sheet

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Intangible Assets34.50 Cr.43.36 Cr.49.62 Cr.65.54 Cr.
Capital Surplus0000
Total Liabilities1970.32 Cr.1614.28 Cr.1312.62 Cr.1771.48 Cr.
Stock Holder Equity2662.96 Cr.1499.07 Cr.1820.60 Cr.2139.82 Cr.
Minority Interest0000
Other Liabilities1115.43 Cr.647.04 Cr.496.61 Cr.904.03 Cr.
Total Assets4633.28 Cr.3113.36 Cr.3133.23 Cr.3911.31 Cr.
Common Stock169.41 Cr.169.40 Cr.169.40 Cr.169.40 Cr.
Retained Earnings01334.54 Cr.1654.02 Cr.1969.27 Cr.
Other Liabilities264.27 Cr.261.55 Cr.263.81 Cr.316.98 Cr.
Good Will0000
Treasury Stock2493.55 Cr.-4.87 Cr.-2.82 Cr.1.15 Cr.
Other Assets565.30 Cr.513.21 Cr.481.64 Cr.469.15 Cr.
Cash2484.51 Cr.405.18 Cr.104.81 Cr.98.77 Cr.
Current Liabilities1698.43 Cr.1332.47 Cr.1021.95 Cr.1454.31 Cr.
Long Term Asset Charges113.15 Cr.103.12 Cr.110.48 Cr.62.22 Cr.
Short Long Term Debt02.40 Lakhs15.30 Lakhs40.60 Lakhs
Other Stockholder Equity2493.55 Cr.-4.87 Cr.-2.82 Cr.1.15 Cr.
Property Plant Equipment325.44 Cr.354.12 Cr.827.08 Cr.1367.09 Cr.
Total Cur. Assets3708.04 Cr.2202.65 Cr.1774.88 Cr.2009.46 Cr.
Long Term Investments0005.50 Lakhs
Net Tangible Assets2628.46 Cr.1455.71 Cr.1770.97 Cr.2074.28 Cr.
Short Term Investments365.59 Cr.732.01 Cr.957.01 Cr.1049.01 Cr.
Net Receivables205.24 Cr.241 Cr.130.41 Cr.210 Cr.
Long Term Debt002.40 Lakhs17.70 Lakhs
Inventory534.70 Cr.546.69 Cr.483.03 Cr.486.49 Cr.
Accounts Payable570.55 Cr.464.47 Cr.357.06 Cr.405.81 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account